College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5E5, Canada.
Saskatoon Cancer Center, Saskatchewan Cancer Agency, University of Saskatchewan, 20 Campus Drive, Saskatoon, SK S7N 4H4, Canada.
Curr Oncol. 2021 May 11;28(3):1803-1822. doi: 10.3390/curroncol28030168.
: Hormone receptor-positive and HER2-negative breast cancer (HR + BC) is the most prevalent breast cancer. Endocrine therapy is the mainstay of treatment, however, due to the heterogeneous nature of the disease, resistance to endocrine therapy is not uncommon. Over the past decades, the emergence of novel targeted therapy in combination with endocrine therapy has shown improvement in outcomes of HR + BC. This paper reviews available data of targeted therapy and the results of pivotal clinical trials in the management of HR + BC. : A literature search in PubMed and Google Scholar was performed using keywords related to HR + BC and targeted therapy. Major relevant studies that were presented in international cancer research conferences were also included. : Endocrine therapy with tamoxifen and aromatase inhibitors are backbone treatments for women with early-stage HR + BC leading to a significant reduction in mortality. They can also be used for primary prevention in women with a high risk of breast cancer. Preliminary data has shown the efficacy of adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitor, abemaciclib, in high-risk disease in combination with aromatase inhibitors. For most women with advanced HR + BC, endocrine therapy is the primary treatment. Recent evidence has shown that the use of CKD 4/6 inhibitors, mTOR inhibitors, and PI3K inhibitors in combination with endocrine therapy has been associated with better outcomes and delays initiation of chemotherapy. Several novel agents are under study for HR + BC. : Targeted treatment options for HR + BC have evolved. The future of overcoming resistance to targeted therapy, novel compounds, and predictive markers are key to improving HR + BC outcomes.
: 激素受体阳性和人表皮生长因子受体 2 阴性乳腺癌（HR + BC）是最常见的乳腺癌。内分泌治疗是主要的治疗方法，然而，由于疾病的异质性，对内分泌治疗的耐药并不少见。在过去的几十年中，新型靶向治疗与内分泌治疗联合应用，改善了 HR + BC 的治疗效果。本文综述了 HR + BC 靶向治疗的现有数据和关键临床试验结果。: 在 PubMed 和 Google Scholar 上使用与 HR + BC 和靶向治疗相关的关键词进行了文献检索，并纳入了在国际癌症研究会议上发表的主要相关研究。: 他莫昔芬和芳香化酶抑制剂等内分泌治疗是早期 HR + BC 女性的主要治疗方法，显著降低了死亡率。它们也可用于乳腺癌高危女性的一级预防。初步数据表明，CDK4/6 抑制剂 abemaciclib 与芳香化酶抑制剂联合用于高危疾病的疗效。对于大多数晚期 HR + BC 女性，内分泌治疗是主要治疗方法。最近的证据表明，CDK4/6 抑制剂、mTOR 抑制剂和 PI3K 抑制剂与内分泌治疗联合使用与更好的结果相关，并延迟了化疗的开始。一些新型药物正在研究用于 HR + BC。: HR + BC 的靶向治疗选择已经发展。克服靶向治疗耐药、新型化合物和预测标志物的未来是改善 HR + BC 结局的关键。
